Any current/future new fundraising through debt or equity?

There is no current plan, desire, or thought of selling any existing facilities to raise funds. The company is managing existing expenditures for ongoing projects without additional major capital expenditure except potentially for creating a pilot R&D plant; timing and decision on this are yet to be finalized. No mention of new fundraising through debt or equity was made in the call. The management is focusing on optimizing current operations and infrastructure to support growth with existing resources. The balance sheet is noted to be leveraged, but no explicit plan for fresh equity or debt i

Any current/future capex/capital investment/strategic investment?

Current CAPEX is limited to necessary expenditures to rejig existing facilities to support committed projects and pipeline vaccines, most of which do not require additional capital expenditure. A significant potential CAPEX involves creating a pilot R&D plant, with timing and decision still under consideration. There is no plan to sell any existing antigen-generating or vaccine manufacturing facilities; repurposing of the human vaccine facility (BSL-3 lab) is underway pending government concurrence. The company is managing other investments within already incurred expenditures and focusi

Future growth expectations in sales/revenue/volumes?

Poultry division is on a recovery path with a positive upswing in vaccine and health product sales expected to continue into FY25. Management anticipates double-digit growth in the domestic poultry vaccine division but refrains from giving specific percentage guidance publicly. The new CuRx LA product is expected to neutralize previous sales losses within one year, contributing to growth. Expansion efforts in African markets are ongoing, with hopes for improved sales once product registrations complete and local teams are hired. Animal Health division shows a 17% growth in health product sales

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a positive upswing in the Poultry division with sustained growth in vaccines and health products sales going forward. Management anticipates double-digit growth in the Poultry Healthcare division but refrains from making specific percentage commitments publicly. New product launches like the modified Newcastle Disease Vaccine and Infectious Bursal Disease vaccine with improved technology are expected to strengthen performance and capture more market share. The Animal Healthcare division is working to neutralize the negative impact of regulatory changes within one year

Current/ Expected Orderbook/ Pending Orders?

In Q3 FY24, Hester Africa had export sales of Rs. 0.73 crores mainly to East African countries. Over 9 months in FY24, export sales totaled about Rs. 4.5 crores. The company has faced overall losses (Rs. 3.6 crores in Q3 and Rs. 13 crores in 9 months) due to unmet sales targets and fixed/variable costs. Registrations for products in African countries are ongoing aggressively. Once registrations are complete, the company expects to start supplying in several countries. There is hope for increased purchases from governments if the situation improves. Challenges include foreign exchange constrain

IN US

Sale is live|00:00:00left today

Hester Biosciences LtdQ4 FY25Pharmaceuticals & Biotechnology

Hester Biosciences Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,953P/E: 38.0Market Cap: ₹1.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Poultry division is on a recovery path with a positive upswing in vaccine and health product sales expected to continue into FY25.
→Management anticipates double-digit growth in the domestic poultry vaccine division but refrains from giving specific percentage guidance publicly.
→The new CuRx LA product is expected to neutralize previous sales losses within one year, contributing to growth.
→Expansion efforts in African markets are ongoing, with hopes for improved sales once product registrations complete and local teams are hired.
→Animal Health division shows a 17% growth in health product sales excluding discontinued brands and is launching line extensions expected to mitigate past sales losses.
→Development of new vaccines and introduction of pet product lines indicate plans for diversification and long-term growth.
→Overall emphasis on stabilizing and growing existing segments, with readiness to invest selectively in infrastructure like pilot R&D plants if needed.

Margin guidance

Category 3

→The company expects a positive upswing in the Poultry division with sustained growth in vaccines and health products sales going forward.
→Management anticipates double-digit growth in the Poultry Healthcare division but refrains from making specific percentage commitments publicly.
→New product launches like the modified Newcastle Disease Vaccine and Infectious Bursal Disease vaccine with improved technology are expected to strengthen performance and capture more market share.
→The Animal Healthcare division is working to neutralize the negative impact of regulatory changes within one year through product launches and market strategies.
→The Pet Care division showed 91% growth over 9 months, indicating a strong growth trajectory despite a slight recent dip.
→International markets, especially Africa, are expected to improve as registration activities conclude, enabling sales expansion.
→Overall, management is optimistic about growth in revenues, profitability, and operational performance, aiming for improved stability and high growth in the coming quarters.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no current plan, desire, or thought of selling any existing facilities to raise funds.
→The company is managing existing expenditures for ongoing projects without additional major capital expenditure except potentially for creating a pilot R&D plant; timing and decision on this are yet to be finalized.
→No mention of new fundraising through debt or equity was made in the call.
→The management is focusing on optimizing current operations and infrastructure to support growth with existing resources.
→The balance sheet is noted to be leveraged, but no explicit plan for fresh equity or debt issuance is indicated.

Order book

→In Q3 FY24, Hester Africa had export sales of Rs. 0.73 crores mainly to East African countries.
→Over 9 months in FY24, export sales totaled about Rs. 4.5 crores.
→The company has faced overall losses (Rs. 3.6 crores in Q3 and Rs. 13 crores in 9 months) due to unmet sales targets and fixed/variable costs.
→Registrations for products in African countries are ongoing aggressively.
→Once registrations are complete, the company expects to start supplying in several countries.
→There is hope for increased purchases from governments if the situation improves.
→Challenges include foreign exchange constraints in key African markets (Egypt, Ethiopia, Nigeria).
→The company is simultaneously pushing domestic sales in Tanzania.
→Focus on private channel sales and creating distributors to overcome tender funding and market constraints.
→Overall, increased order fulfillment and supply are expected once registration hurdles are cleared in the next two quarters.

Capex plans

Yes

→Current CAPEX is limited to necessary expenditures to rejig existing facilities to support committed projects and pipeline vaccines, most of which do not require additional capital expenditure.
→A significant potential CAPEX involves creating a pilot R&D plant, with timing and decision still under consideration.
→There is no plan to sell any existing antigen-generating or vaccine manufacturing facilities; repurposing of the human vaccine facility (BSL-3 lab) is underway pending government concurrence.
→The company is managing other investments within already incurred expenditures and focusing on efficiency.
→Recruitment investments are planned mainly for expanding sales infrastructure in African markets once product registrations are completed, but these are operational expenses rather than CAPEX.

How does Hester Biosciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hester Biosciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hester Biosciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio